Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Open accessAbstract
Background Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating intravitreal faricimab with extension up to every 16 weeks for neovascular age-related macular degeneration (nAMD).Methods TENAYA and LUCERNE were randomised, double-masked, non-inferiority trials across 271 sites worldwide. Treatment-naive patients with nAMD aged 50 years or older were randomly assigned (1:1) to intravitreal faricimab 6·0 mg up to every 16 weeks, based on protocol-defined disease activity assessments at weeks 20 and 24, or aflibercept 2·0 mg every 8 weeks. Randomisation was performed through an interactive voice or web-based response system using a stratified permuted block randomisation method. Patients, investigators, those assessing outcomes, and the funder were masked to group assignments. The primary endpoint was mean change in best-corrected visual acuity (BCVA) from baseline averaged over weeks 40, 44, and 48 (prespecified non-inferiority margin of four letters), in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. These trials are registered with ClinicalTrials.gov (TENAYA NCT03823287 and LUCERNE NCT03823300).Findings Across the two trials, 1329 patients were randomly assigned between Feb 19 and Nov 19, 2019 (TENAYA n=334 faricimab and n=337 aflibercept), and between March 11 and Nov 1, 2019 (LUCERNE n=331 faricimab and n=327 aflibercept). BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mean change 5·8 letters [95% CI 4·6 to 7·1] and 5·1 letters [3·9 to 6·4]; treatment difference 0·7 letters [-1·1 to 2·5]) and LUCERNE (6·6 letters [5·3 to 7·8] and 6·6 letters [5·3 to 7·8]; treatment difference 0·0 letters [-1·7 to 1·8]). Rates of ocular adverse events were comparable between faricimab and aflibercept (TENAYA n=121 [36·3%] vs n=128 [38·1%], and LUCERNE n=133 [40·2%] vs n=118 [36·2%]).Interpretation Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with nAMD.Funding F Hoffmann-La Roche.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A loss of ≥5 or >5 letters has often been used to guide treatment decisions in randomized controlled trials, and a margin of four letters is commonly used to reflect noninferiority in randomized controlled trials comparing active treatments.
“However, a loss of ≥5 or >5 letters has often been used to guide treatment decisions in randomized controlled trials,27,28 and a margin of four letters is commonly used to reflect noninferiority in randomized controlled trials comparing active treatments.29,30”
From <i>ANO2</i> Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [30]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886 · see citing works
Self-citationRanibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669 · see citing works
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · see citing works
Self-citationAge-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,572 · see citing works
Self-citationDugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931 · see citing works
Self-citationRegillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858 · see citing works
Self-citationHolz, F. G., Tadayoni, R., Beatty, S., Berger, A. R., Cereda, M. G., Cortez, R. T., Hoyng, C. B., Hykin, P. G., Staurenghi, G., Heldner, S., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305327 · Cited by 618 · see citing works
Self-citationMolecular pathogenesis of retinal and choroidal vascular diseases
Campochiaro, P. A. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.002 · Cited by 553 · see citing works
Self-citationBusbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500 · see citing works
Self-citationSchäfer, W. M., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G. J., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 485 · see citing works
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
Regula, J. T., von Leithner, P. L., Foxton, R. H., Barathi, V. A., Cheung, C. M. G., Tun, S. B. B., Wey, Y. S., Iwata, D., Dostálek, M., Moelleken, J., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505889 · Cited by 376 · see citing works
Self-citationSinger, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., & Tuomi, L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.016 · Cited by 356 · see citing works
Self-citationJoussen, A. M., Ricci, F., Paris, L. P., Korn, C., Quezada-Ruiz, C., & Zarbin, M. A. (2021) · Eye · doi:10.1038/s41433-020-01377-x · Cited by 299 · see citing works
Self-citationWykoff, C. C., Croft, D. E., Brown, D. M., Wang, R. C., Payne, J. F., Clark, L., Abdelfattah, N. S., & Sadda, S. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.08.009 · Cited by 274 · see citing works
Self-citationTreat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration
da Silva, R. M., Berta, A., Larsen, M., Macfadden, W., Feller, C., & Monés, J. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.07.014 · Cited by 262 · see citing works
Self-citationOkada, M., Mitchell, P., Finger, R. P., Eldem, B. M., Talks, J. S., Hirst, C., Paladini, L. M., Barratt, J., Wong, T. Y., & Loewenstein, A. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.07.060 · Cited by 212 · see citing works
Self-citationCiulla, T. A., Hussain, R. M., Pollack, J. S., & Williams, D. F. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.05.017 · Cited by 202 · see citing works
Prenner, J. L., Halperin, L. S., Rycroft, C. E., Hogue, S., Liu, Z. W., & Seibert, R. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.06.023 · Cited by 192 · see citing works
Khanani, A. M., Patel, S. S., Ferrone, P. J., Osborne, A., Sahni, J., Grzeschik, S., Basu, K., Ehrlich, J. S., Haskova, Z., & Dugel, P. U. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2699 · Cited by 183 · see citing works
Self-citationSahni, J., Dugel, P. U., Patel, S. S., Chittum, M. E., Berger, B., del Valle Rubido, M., Sadikhov, S., Szczesny, P., Schwab, D., Nogoceke, E., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2685 · Cited by 129 · see citing works
Self-citationGillies, M. C., Hunyor, A. P., Arnold, J., Guymer, R. H., Wolf, S., Ng, P., Pecheur, F. L., & McAllister, I. L. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6776 · Cited by 127 · see citing works
Self-citationTHE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES
Heier, J. S., Singh, R. P., Wykoff, C. C., Csaky, K. G., Lai, T. Y. Y., Loewenstein, A., Schlottmann, P. G., Paris, L. P., Westenskow, P. D., & Quezada-Ruiz, C. (2020) · Retina · doi:10.1097/iae.0000000000003003 · Cited by 118 · see citing works
Self-citationAugsburger, M., Sarra, G., & Imesch, P. D. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04404-0 · Cited by 102 · see citing works
Khanani, A. M., Skelly, A., Bezlyak, V., Griner, R., Torres, L. R., & Sagkriotis, A. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2019.09.009 · Cited by 96 · see citing works
Self-citationKhanani, A. M., Guymer, R. H., Basu, K., Boston, H., Heier, J. S., Korobelnik, J., Kotecha, A., Lin, H., Silverman, D. G., Swaminathan, B., et al. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100076 · Cited by 86 · see citing works
Self-citationDaïen, V., Finger, R. P., Talks, J. S., Mitchell, P., Wong, T. Y., Sakamoto, T., Eldem, B., & Korobelnik, J. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317434 · Cited by 76 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- American Society of Retina Specialists. Member update: Novartis- appointed safety review committee reports initial brolucizumab findings. 2020. https://www.brolucizumab.info/sites/ brolucizumab_info/files/2020-07/ASRS_SRC_report.pdf (accessed June 25, 2021).
Cited by
Sorted by citations
Meer, E. A., Oh, D. H., & Brodie, F. L. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s384995 · Cited by 21 · see citing works
Sivaprasad, S., Bailey, C., Downey, L., Gilbert, R., Gale, R., Kotagiri, A., Mahmood, S., Morgan-Warren, P., Napier, J., Narendran, N., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2362278 · Cited by 15 · see citing works
Self-citationGuymer, R. H., Silva, R., Ghadessi, M., Leal, S., Gashaw, I., Damask, A., Paulding, C., & Rittenhouse, K. D. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.8.17 · Cited by 6 · see citing works
“29,30 The lack of identification of specific high-risk alleles of genes (including ARMS2/HTRA1 , CFH , and VEGFA ) that predict response to anti-VEGF therapy may not be surprising, given the well-acknowledged heterogeneity in results from different studies examining this topic.”
- Authors
- Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., Lai, T. Y. Y., Silverman, D., Regillo, C., Swaminathan, B., Viola, F., Cheung, C. M. G., Wong, T. Y., Abbey, A., Abdulaeva, E., Abraham, P., Adan Civera, A., Agostini, H., Alezzandrini, A., Alfaro, V., Almony, A., Altay, L., Amini, P., Antoszyk, A., Aradi, E., Arias, L., Arnold, J., Asaria, R., Astakhov, S., Astakhov, Y., Awh, C. C., Balaratnasingam, C., Banerjee, S., Baumal, C., Becker, M., Belfort, R., Bratko, G., Bridges, W. J. Z., Brown, J., Brown, D. M., Budzinskaya, M., Buffet, S., Burgess, S., Byon, I., Cagini, C., Calzada, J., Cameron, S., Campochiaro, P., Carlson, J., Carneiro, A., Chan, C., Chang, E., Chang, A., Chao, D., Chaudhry, N., Chee, C., Cheek, A., Chen, S.-J., Chen, S.-N., Cheung, G., Chexal, S., Chittum, M., Chow, D., Cole, A., Connolly, B., Cornut, P. L., Couvillion, S., Danzig, C., Daskalov, V., Dessouki, A., Devin, F., Dollin, M., Dolz, R., Downey, L., Dreyer, R., Dugel, P., Eichenbaum, D., Eldem, B., Engstrom, R., Escobar, J. J., Eter, N., Faber, D. W., Falk, N., Feiner, L., Fernandez Vega, A., Ferrone, P., Figueroa, M., Fine, H., Fineman, M., Fox, G. M., Francais, C., Franco, P., Fraser-Bell, S., Fung, N., Furno Sola, F., Gale, R., Garcia-Layana, A., Garcia-Layana, A., Gasperini, J., Gawecki, M., Ghanchi, F., Gill, M., Giunta, M., Glaser, D., Goldstein, M., Gomez Ulla, F., Gomi, F., Gonzalez, V., Graff, J., Gupta, S., Guthoff, R., Guymer, R., Haas, A., Hampton, R., Hatz, K., Hayashi, K., Heier, J., Herba, E., Hershberger, V., Higgins, P., Holekamp, N., Honda, S., Howard, J., Hu, A., Huddleston, S., Iida, T., Imaizumi, H., Ito, Y., Ito, Y., Itty, S., Javey, G., Javid, C., Kaga, T., Kaluzny, J., Kang, S. W., Kapoor, K., Karabas, L., Kawasaki, T., Kelty, P., Kerenyi, A., Khanani, A., Khoramnia, R., Khurana, R., Kimura, K., Klein-Mascia, K., Kobayashi, N., Kodjikian, L., Koizumi, H., Kokame, G., Kulikov, A., Kwong, H., Kwun, R., Lai, T., Lai, C.-C., Lalonde, L., Lanzetta, P., Larsen, M., Lavina, A., Lee, W. K., Lee, J. E., Lee, S., Levy, J., Lindsell, L., Liu, M., London, N., Lotery, A., Lozano Rechy, D., Luckie, A., Maberley, D., Maeno, T., Mahmood, S., Makkouk, F., Marcus, D., Margherio, A., Masse, H., Matsubara, H., Maturi, R., Mehta, S., Menon, G., Mentes, J., Michels, M., Mitamura, Y., Mitchell, P., Mohamed, Q., Mones, J., Montemayor Lobo, R., Montero, J., Moore, J., Mori, R., Morori-Katz, H., Mukherjee, R., Murata, T., Muzyka-Wozniak, M., Nardi, M., Narendran, N., Nicolo, M., Nielsen, J., Nishimura, T., Noda, K., Nowinska, A., Oh, H., Ohr, M., Okada, A., Oleksy, P., Ono, S., Ozdek, S., Ozturk, B., Pablo, L., Park, K. H., Parke, D. W., Parravano, M. C., Patel, P., Patel, A., Patel, S., Patel, S., Pauleikhoff, D., Pearce, I., Pearlman, J., Petkova, I., Pieramici, D., Pozdeyeva, N., Qureshi, J., Raczynska, D., Ramirez Estudillo, J., Rathod, R., Razavi, H., Regillo, C., Reilly, G., Ricci, F., Rich, R., Romanowska-Dixon, B., Rosenblatt, I., Ruiz Moreno, J. M., Sacu, S., Saedon, H., Saeed, U., Sagong, M., Sakamoto, T., Sandhu, S., Sararols, L., Saravia, M., Schadlu, R., Schlottmann, P., Sekiryu, T., Seres, A., Sermet, F., Shah, S., Shah, R., Shah, A., Sheidow, T., Sheth, V., Shiragami, C., Sikorski, B., Silva, R., Singerman, L., Sisk, R., Sisk, R., Sørensen, T. L., Souied, E., Spinak, D.-J., Staurenghi, G., Steinmetz, R., Stoller, G., Stoltz, R., Suan, E., Suner, I., Suzanne, Y., Tadayoni, R., Takahashi, K., Takayama, K., Taleb, A., Talks, J., Terasaki, H., Thompson, J., Toth-Molnar, E., Tran, K., Tuli, R., Uchiyama, E., Vajas, A., Van Lith-Verhoeven, J., Varsanyi, B., Viola, F., Virgili, G., Vogt, G., Völker, M., Warrow, D., Weber, P., Wells, J. A., Wickremasinghe, S., Wieland, M., Williams, G., Williams, T., Wong, D., Wong, K., Wong, J., Wong, I., Wong, R., Wowra, B., Wykoff, C. C., Yamashita, A., Yasuda, K., Yilmaz, G., Yiu, G., Yoneda, A., Yoon, Y. H., Yoreh, B., Yu, H., Yu, S. Y., Yurieva, T., Zambrano, A., Zatorska, B., & Zeolite, C.
- Affiliations
- Ophthalmic Consultants of Boston (US)
- University of Nevada, Reno (US)
- Roche (Ireland) (IE)
- Vitreous Retina Macula Consultants of New York (US)
- Genentech (US)
- Hospital Universitario Ramón y Cajal (ES)
- University of Bonn (DE)
- Roche (United Kingdom) (GB)
- Chinese University of Hong Kong (HK)
- Roche (Canada) (CA)
- National University of Singapore (SG)
- Corresponding author
- Heier, Jeffrey S
- ORCID
- Brittain, Christopher
- Silverman, David
- Brown, David M.
- Cagini, Carlo
- Chang, Emmanuel
- Chao, Daniel
- Eter, Nicole
- Guymer, Robyn
- Khoramnia, Ramin
- Kodjikian, Laurent
- Lotery, Andrew
- Mahmood, Sajjad
- Maturi, Raj
- Ohr, Matthew
- Patel, Praveen
- Sacu, Stefan
- Sararols, Laura
- Schlottmann, Patricio
- Seres, András
- Sikorski, Bartosz
- Souied, Eric
- Tadayoni, Ramin
- Talks, James
- Virgili, Gianni
- Wickremasinghe, Sanjeewa
- Wykoff, Charles C.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 399
- Issue
- 10326
- Pages
- 729-740
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206959584
- Cited by
- 785
- References
- 26
- Citations by year
- 2026: 197 · 2025: 228 · 2024: 188 · 2023: 126 · 2022: 45
- FWCI
- 131.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- F. Hoffmann-La Roche Ltd
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal and Macular Surgery
- Keywords
- faricimab, neovascular age-related macular degeneration, intravitreal injection, angiopoietin-2, VEGF-A, aflibercept, extended dosing interval, best-corrected visual acuity, non-inferiority, treatment safety, anti-VEGF therapy, disease activity assessment, retinal pigment epithelium, choroidal neovascularization, macular edema
- MeSH terms
- Aged, Aged, 80 and over, Double-Blind Method, Drug Administration Schedule, Female, Humans, Macular Degeneration, Male, Recombinant Fusion Proteins, Visual Acuity, Treatment Outcome, Antibodies, Bispecific, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Angiopoietin-2, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
